On Monday, Gilead Sciences Inc. GILD and Merck & Co. Inc. MRK on Monday discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study ...
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results